ZAI LAB (09688.HK) shares surged 5.50% in the intraday trading session, as the pharmaceutical sector experienced a significant rally. The biotech company's stock price increase aligns with the broader positive sentiment in the pharma industry, suggesting investor optimism in the sector.

The pharmaceutical sector witnessed a widespread rally, with several companies posting substantial gains. Sino Biopharm led the pack with an impressive 13% increase, while ZAI LAB and Immunotech both saw their shares climb by 5%. Other notable performers included Dualitybio and Grand Pharma, each recording a 4% rise, while Ascletis, Remegen, and Beigene all gained 3%.

This sector-wide upswing indicates a renewed interest in pharmaceutical and biotech stocks, possibly driven by positive industry developments or favorable market conditions. Investors appear to be showing confidence in the growth potential and innovation within the pharmaceutical industry, with ZAI LAB benefiting from this positive momentum.